Market revenue in 2023 | USD 428.8 million |
Market revenue in 2030 | USD 711.2 million |
Growth rate | 7.5% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Thermo Fisher Scientific Inc, IQVIA Holdings Inc, Clara Health, Antidote Health, BBK Worldwide, Clariness, Costas Inc, Worldwide Clinical Trials, Veristat, Elligo Health Research |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clinical trial patient recruitment services market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 57.37% in 2023. Horizon Databook has segmented the U.S. clinical trial patient recruitment services market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. accounts for the largest share of the global clinical trial patient recruitment services market, as many pharmaceutical & life sciences companies are present in this country. The presence of established CROs in the U.S. providing clinical trial recruitment services further supports market growth in the country.
According to estimates by Clinicaltrial.gov, as of July 2023, the U.S. accounted for the majority of clinical trials; the U.S. alone accounted for 31% of total clinical trials globally. A high percentage of clinical trials across the U.S. is creating lucrative opportunities for the clinical trial patient recruitment services market.
High R&D spending on clinical trials has further fueled the local market. For instance, in October 2021, the U.S. FDA approved 11 new clinical trial research, resulting in over USD 25 million in funding over the next 4 years.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. clinical trial patient recruitment services market , including forecasts for subscribers. This country databook contains high-level insights into U.S. clinical trial patient recruitment services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account